Patents by Inventor Andrew Marcus

Andrew Marcus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250042673
    Abstract: Apparatus for sorting articles includes a conveyor having a plurality of article support members, each article support member provided to extend longitudinally parallel to a direction of movement of the conveyor, the support members being provided spaced 5 transversely across a conveyor and being pivotable at a first end about a transverse axis to unload the article from the conveyor.
    Type: Application
    Filed: December 12, 2022
    Publication date: February 6, 2025
    Inventors: Hamish Alexander Nigel KENNEDY, Finn Marcus KENNEDY, Andrew David MCINTYRE
  • Publication number: 20230174541
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 8, 2023
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Patent number: 11535614
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 27, 2022
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Patent number: 11479557
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Patent number: 11459253
    Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 4, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Chen Zhou, Andrew Marcus, Bruce Rittmann, Zhaocheng Wang, Aura Ontiveros-Valencia, Rosa Krajmalnik-Brown
  • Publication number: 20210401532
    Abstract: A protective equipment includes a rotatable window and an extended member secured to a peripheral edge of the rotatable window. The rotatable window may be configured as a shield to be disposed between a patient and a healthcare worker to minimize exposure of the healthcare worker to at least one of the patient's bodily fluids, bacteria, and viruses. A port provides entrance by one or more instruments through the rotatable window or the extended member, thereby providing access to the patient while protecting the healthcare worker from the patient's bodily fluids, bacteria and/or viruses. The protective equipment may include an air flow system configured to receive and filter air expelled by the patient, to pull the expelled air away from the patient's face and to filter/clean the expelled air.
    Type: Application
    Filed: June 24, 2021
    Publication date: December 30, 2021
    Applicant: LevMarc LLC
    Inventors: Steven Brian Levine, Andrew Marcus
  • Patent number: 11155135
    Abstract: A traction system is provided for a rail draft vehicle including an engine with a driveshaft, at least a pair of rubber-tired traction wheels, and at least one rail guide wheel pressurized relative to the vehicle by at least one fluid-powered cylinder. Included in the system are a programmable processor connected to a driveshaft speed sensor, a rail guide wheel speed sensor, an engine throttle controller, a fluid-powered cylinder controller and a vehicle control panel. The processor is constructed and arranged for automatically adjusting the engine throttle controller in coordination with the fluid-powered cylinder controller for achieving movement of the rail draft vehicle from a dead stop position by increasing applied vehicle weight upon the traction wheels by the at least one fluid-powered cylinder and adjusting engine RPM's until the vehicle begins movement as detected by the rail guide wheel speed sensor.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 26, 2021
    Assignee: NORDCO INC.
    Inventors: Michael Terrence Blouin, Andrew Marcus Noyes, Lee William Campbell, Joel Wesley Frank, Eric John Slocombe
  • Publication number: 20210238174
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: September 9, 2020
    Publication date: August 5, 2021
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Publication number: 20210179463
    Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.
    Type: Application
    Filed: February 2, 2017
    Publication date: June 17, 2021
    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Chen Zhou, Andrew Marcus, Bruce Rittmann, Zhaocheng Wang, Aura Ontiveros-Valencia, Rosa Krajmalnik-Brown
  • Patent number: 11001583
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: May 11, 2021
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
  • Publication number: 20210090011
    Abstract: Disclosed is a system for identifying and tracking items using unique product identifiers. In some embodiments, the system includes a central unit and an external unit. The central unit is coupled to the external unit. The external unit includes a plurality of products. The central unit is configured to generate a plurality of unique product identifiers (IDs). The central unit is further configured to authorize the external unit to access the plurality of unique IDs. Upon authorizing, the central unit accesses the plurality of unique IDs and assigns each of the plurality of unique IDs to a product of a plurality of products.
    Type: Application
    Filed: September 25, 2019
    Publication date: March 25, 2021
    Inventor: Andrew Marcus Fletcher Rae
  • Publication number: 20210053974
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 1, 2020
    Publication date: February 25, 2021
    Applicant: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Publication number: 20200339566
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: January 24, 2020
    Publication date: October 29, 2020
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Patent number: 10807980
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 20, 2020
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Patent number: 10683302
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 16, 2020
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Publication number: 20200172535
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 4, 2020
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Publication number: 20200079767
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Application
    Filed: April 25, 2019
    Publication date: March 12, 2020
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
  • Publication number: 20190375257
    Abstract: A traction system is provided for a rail draft vehicle including an engine with a driveshaft, at least a pair of rubber-tired traction wheels, and at least one rail guide wheel pressurized relative to the vehicle by at least one fluid-powered cylinder. Included in the system are a programmable processor connected to a driveshaft speed sensor, a rail guide wheel speed sensor, an engine throttle controller, a fluid-powered cylinder controller and a vehicle control panel. The processor is constructed and arranged for automatically adjusting the engine throttle controller in coordination with the fluid-powered cylinder controller for achieving movement of the rail draft vehicle from a dead stop position by increasing applied vehicle weight upon the traction wheels by the at least one fluid-powered cylinder and adjusting engine RPM's until the vehicle begins movement as detected by the rail guide wheel speed sensor.
    Type: Application
    Filed: April 26, 2019
    Publication date: December 12, 2019
    Inventors: Michael Terrence BLOUIN, Andrew Marcus NOYES, Lee William CAMPBELL, Joel Wesley FRANK, Eric John SLOCOMBE
  • Patent number: 10399976
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 3, 2019
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Publication number: 20190144459
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston